Florence Van Obbergh1, Laurent Knoops2, Timothy Devos3, Yves Beguin4, Carlos Graux5, Fleur Benghiat6, Khalil Kargar-Samani7, Deborah Bauwens8, André Efira9, Christian Dubois10, Cécile Springael11, Luc Montfort12, Thierry Connerotte13, Arnaud Capron14, André Delannoy15, Pierre Wallemacq14. 1. Hematology Department of CH Jolimont, La Louvière, Belgium. 2. Hematology Department of Cliniques, Universitaires St Luc, Brussels, Belgium. 3. Hematology Department of UZ Leuven, Belgium. 4. Hematology Department of CHU Liège, Belgium. 5. Hematology Department of CHU Dinant Godinne, Belgium. 6. Hematology Department of CHU Erasme, Brussels, Belgium. 7. Hematology Department of CHWAPI, Tournai, Belgium. 8. Hematology Department of Clinique St Jean, Brussels, Belgium. 9. Hematology Department of CHU Brugmann, Brussels, Belgium. 10. Hematology Department of Cliniques de l'Europe, Brussels, Belgium. 11. Hematology Department of CHU Tivoli, La Louvière, Belgium. 12. Hematology Department of St Luc, Bouge, Belgium. 13. Hematology Department of St Pierre, Ottignies, Belgium. 14. Clinical Chemistry Department, Cliniques Universitaires St Luc, Brussels, Belgium. 15. Hematology Department of CH Jolimont, La Louvière, Belgium. Electronic address: adelannoy222@gmail.com.
Abstract
This retrospective multicenter study in patients with chronic myeloid leukemia in chronic phase was undertaken to confirm the clinical relevance of imatinib plasma concentrations monitoring in daily practice. Forty-one patients, with 47 imatinib plasma measurements, were analyzed during treatment with imatinib given at a fixed 400mg daily dose. A significant inverse relationship of imatinib concentration with the patients' weight was observed (Pearson's test: p=0.02, R2=0.1). More interestingly, patients with poor response (switched to another tyrosine kinase inhibitor because of imatinib failure, or because of disease progression after an initial response) displayed a significantly lower mean imatinib concentration as compared to patients maintained on imatinib (822ng/mL vs 1099ng/mL; Student's t-test, p=0.04). Failure or disease progression occurred more often in patients in the lowest quartile of imatinib concentrations compared to patients in the highest quartile (p=0.02, logrank test). No correlation could be established with other biological or clinical parameter, including complete cytogenic response and major molecular response. IN CONCLUSION: in patients treated with imatinib at a fixed daily dose of 400mg, imatinib plasma concentrations decreased with increasing body weight and were lower in patients switched to another tyrosine kinase inhibitor due to imatinib failure. Systematic determination of imatinib plasma trough levels should be encouraged in such patients.
This retrospective multicenter study in patients with chronic myeloid leukemia in chronic phase was undertaken to confirm the clinical relevance of imatinib plasma concentrations monitoring in daily practice. Forty-one patients, with 47 imatinib plasma measurements, were analyzed during treatment with imatinib given at a fixed 400mg daily dose. A significant inverse relationship of imatinib concentration with the patients' weight was observed (Pearson's test: p=0.02, R2=0.1). More interestingly, patients with poor response (switched to another tyrosine kinase inhibitor because of imatinibfailure, or because of disease progression after an initial response) displayed a significantly lower mean imatinib concentration as compared to patients maintained on imatinib (822ng/mL vs 1099ng/mL; Student's t-test, p=0.04). Failure or disease progression occurred more often in patients in the lowest quartile of imatinib concentrations compared to patients in the highest quartile (p=0.02, logrank test). No correlation could be established with other biological or clinical parameter, including complete cytogenic response and major molecular response. IN CONCLUSION: in patients treated with imatinib at a fixed daily dose of 400mg, imatinib plasma concentrations decreased with increasing body weight and were lower in patients switched to another tyrosine kinase inhibitor due to imatinibfailure. Systematic determination of imatinib plasma trough levels should be encouraged in such patients.
Authors: Kurt A Jaeckle; S K Anderson; Erin L Twohy; Jesse G Dixon; Caterina Giannini; Robert Jenkins; Merrill J Egorin; Jann N Sarkaria; Paul D Brown; P J Flynn; John Schwerkoske; Jan C Buckner; Evanthia Galanis Journal: J Neurooncol Date: 2019-05-22 Impact factor: 4.130
Authors: Remy B Verheijen; Huixin Yu; Jan H M Schellens; Jos H Beijnen; Neeltje Steeghs; Alwin D R Huitema Journal: Clin Pharmacol Ther Date: 2017-09-07 Impact factor: 6.875
Authors: Ana P Azevedo; Alice Reichert; Celina Afonso; Maria D Alberca; Purificação Tavares; Fernando Lima Journal: Clin Med Insights Oncol Date: 2017-04-06